Jo PalmerPhillips - Eliem Therapeutics Chief Officer
| ELYMDelisted Stock | USD 3.08 0.08 2.67% |
Insider
Jo PalmerPhillips is Chief Officer of Eliem Therapeutics
| Phone | 877 354 3689 |
| Web | https://eliemtx.com |
Eliem Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2454) % which means that it has lost $0.2454 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3835) %, meaning that it created substantial loss on money invested by shareholders. Eliem Therapeutics' management efficiency ratios could be used to measure how well Eliem Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Erin JD | Shattuck Labs | 44 | |
| Caroline Godfrey | PepGen | N/A | |
| Michael Gait | PepGen | N/A | |
| Man MBA | Adagene | 47 | |
| Patrick Amstutz | Molecular Partners AG | 49 | |
| Alexander Zurcher | Molecular Partners AG | 49 | |
| Hing Wong | HCW Biologics | 70 | |
| Timothy MBA | Aerovate Therapeutics | 62 | |
| David MBA | Champions Oncology | 55 | |
| MD MPH | MediciNova | 56 | |
| Kenneth JD | Century Therapeutics | N/A | |
| Casi DeYoung | Shattuck Labs | 53 | |
| Benjamin Dake | Aerovate Therapeutics | 48 | |
| Joseph Zakrzewski | AN2 Therapeutics | 62 | |
| Thomas Shenk | Pmv Pharmaceuticals | 77 | |
| Noel MBA | PepGen | 54 | |
| Kyle Breidenstine | PepGen | N/A | |
| Andrew MBA | Shattuck Labs | 38 | |
| John CPA | MediciNova | N/A | |
| Jennifer Cormier | PepGen | N/A | |
| Anne Lesage | Pharvaris BV | 63 | |
Management Performance
| Return On Equity | -0.38 | |||
| Return On Asset | -0.25 |
Eliem Therapeutics Leadership Team
Elected by the shareholders, the Eliem Therapeutics' board of directors comprises two types of representatives: Eliem Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eliem. The board's role is to monitor Eliem Therapeutics' management team and ensure that shareholders' interests are well served. Eliem Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eliem Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Erin Lavelle, COO VP | ||
| MD MBA, Chief Officer | ||
| James JD, Gen VP | ||
| Jo PalmerPhillips, Chief Officer | ||
| Andrew MD, Principal Chairman | ||
| Valerie Morisset, Chief Development | ||
| Emily Pimblett, Principal Officer | ||
| BAO BCh, President CEO | ||
| Susan MS, VP Affairs | ||
| Robert MBA, CEO Pres | ||
| MBA MD, Interim Officer | ||
| Nishi MD, Senior Development |
Eliem Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Eliem Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.38 | |||
| Return On Asset | -0.25 | |||
| Current Valuation | 122.66 M | |||
| Shares Outstanding | 67.06 M | |||
| Shares Owned By Insiders | 10.38 % | |||
| Shares Owned By Institutions | 77.67 % | |||
| Number Of Shares Shorted | 1.15 M | |||
| Price To Book | 1.56 X | |||
| EBITDA | (40.27 M) | |||
| Net Income | (35.12 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eliem Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Other Consideration for investing in Eliem Stock
If you are still planning to invest in Eliem Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eliem Therapeutics' history and understand the potential risks before investing.
| CEOs Directory Screen CEOs from public companies around the world | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |